Engraftment Syndrome Following Autologous Stem Cell Transplantation in a Patient Receiving Nivolumab as Salvage Therapy
- PMID: 40497705
- PMCID: PMC12671266
- DOI: 10.4274/tjh.galenos.2025.2025.0166
Engraftment Syndrome Following Autologous Stem Cell Transplantation in a Patient Receiving Nivolumab as Salvage Therapy
Keywords: Engraftment syndrome; Immune checkpoint inhibitors; Autologous stem celltransplantation.
Conflict of interest statement
No conflict of interest was declared by the authors.
Figures
References
-
- Mongkolrat S, Tantiworawit A, Niprapan P, Piriyakhuntorn P, Punnachet T, Hantrakun N, Rattanathammethee T, Hantrakool S, Chai-Adisaksopha C, Rattarittamrong E, Norasetthada L. Engraftment syndrome in autologous hematopoietic stem cell transplant patients: incidence, associated risk factors, features, and outcomes. Ann Transplant. 2024;29:e944043–1. doi: 10.12659/AOT.944043. - DOI - PMC - PubMed
-
- Taranto E, Hwang WT, Alfaro M, Surapaneni AS, Kaur Gill S, Feldman T, Randall MP, Spinner MA, Furqan F, Shah NN, Samara Y, Mei MG, Herrera AF, Moskowitz A, Shah GL, Svoboda J. Engraftment syndrome during autologous stem cell transplant in Hodgkin lymphoma patients treated with checkpoint inhibitors: a multi-center retrospective analysis. Blood. 2023;142(Suppl 1):3603. doi: 10.1182/blood-2023-187199. - DOI
LinkOut - more resources
Full Text Sources